Portola Anticipates "Best In Class" Status For Oral Anticoagulant Betrixaban
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Portola Pharmaceuticals is launching a 500-patient Phase II safety and efficacy trial for its novel oral Factor Xa inhibitor anticoagulant betrixaban, touting the compound's potential for three significant areas of differentiation from other late-stage candidates in the crowded anti-thrombotic class